---
title: "ACTPlus - Reviews, Revenue and Downloads in Germany | Apple App Store"
description: "This application has been used for over ten years in a cardiac catheterisation laboratory to achieve a desired activated clotting time (ACT) within the range of 300 - 400 seconds after a single dose o"
---

# ACTPlus — Germany

![ACTPlus App Icon](https://is1-ssl.mzstatic.com/image/thumb/Purple221/v4/fd/30/f6/fd30f68b-160d-b7f7-649a-3d6a030f7d45/AppIcon-0-0-1x_U007emarketing-0-8-0-85-220.png/434x0w.png)

**Developer:** [Philip Cumpston](https://apptail.io/developer/philip-cumpston-YxT)
**Category:** Medical
**Rating:** N/A (0 ratings)
**Price:** €5.99
**Bundle ID:** com.JHLConsultants.ACTPlus
**Store:** Apple App Store
**Country:** Germany
**Version:** 7.4.1 (released 2025-02-06)
**Original Release:** 2025-02-06
**Languages:** English, Dutch, Greek (modern), Spanish, Italian, German, Norwegian Bokmål, Turkish, Chinese, French, Japanese

**App Store Link:** [Download on Apple App Store](https://apps.apple.com/de/app/app/id6741243912)
**AppTail Page:** [https://apptail.io/app/actplus-cxvv/germany](https://apptail.io/app/actplus-cxvv/germany)

## ACTPlus Description
This application has been used for over ten years in a cardiac catheterisation laboratory to achieve a desired activated clotting time (ACT) within the range of 300 - 400 seconds after a single dose of heparin over 86% of the time. If the Act falls short, it can be used to reliably give the next dose that will achieve the desired result. At completion of the procedure, it reliably indicates a dose of protamine that will return the ACT to the pre-heparin state. It has also been used to identify the dos elf heparin nd protamine in a small cardiac bypass series. The following references are available:

1. Cumpston P, Phillips KP. A Novel Method for Calculating Heparin Dosing to Rapidly Achieve Target Anticoagulation for Cardiac Procedures. Journal of Atrial Fibrillation. 2024;18. 

2. Cumpston P. Blood volume estimation in cardiac surgery – A comparative analysis. Perfusion [Internet]. 2023 Apr [cited 2024 Mar 29];38(3):455–63. Available from: 

## ACTPlus Screenshots
- [Screenshot 1](https://is1-ssl.mzstatic.com/image/thumb/PurpleSource221/v4/96/72/38/967238e1-9c2e-20b1-3b93-69240c8e0063/iPhoneXs.jpg/1320x2868.png)
- [Screenshot 2](https://is1-ssl.mzstatic.com/image/thumb/PurpleSource211/v4/44/aa/3e/44aa3e7e-4bb6-4217-3ec5-a1738e3febd2/CleanShot_2025-01-31_at_07.44.01@2x.jpg/1320x2868.png)
- [Screenshot 3](https://is1-ssl.mzstatic.com/image/thumb/PurpleSource221/v4/bf/47/89/bf47895d-56e3-5e68-155f-6d9c23edda45/CleanShot_2025-01-31_at_07.44.33@2x.jpg/1320x2868.png)
- [Screenshot 4](https://is1-ssl.mzstatic.com/image/thumb/PurpleSource221/v4/e9/bd/52/e9bd52fa-97b3-2b73-34ae-14310934915c/CleanShot_2025-01-31_at_07.45.40@2x.jpg/1320x2868.png)
- [Screenshot 5](https://is1-ssl.mzstatic.com/image/thumb/PurpleSource221/v4/d9/8c/8b/d98c8b56-8f8e-8b83-edee-e70172f40595/CleanShot_2025-01-31_at_07.45.59@2x.jpg/1320x2868.png)
- [Screenshot 6](https://is1-ssl.mzstatic.com/image/thumb/PurpleSource211/v4/51/6a/c4/516ac46d-4365-ebf4-3309-e1d81a4f4b20/CleanShot_2025-01-31_at_07.47.18@2x.jpg/1320x2868.png)
- [Screenshot 7](https://is1-ssl.mzstatic.com/image/thumb/PurpleSource221/v4/0a/02/78/0a0278d0-55ea-38f3-ab21-a00916b45a4b/CleanShot_2025-01-31_at_07.44.33@2x.jpg/1320x2868.png)
- [Screenshot 8](https://is1-ssl.mzstatic.com/image/thumb/PurpleSource221/v4/72/af/cf/72afcfe5-f48f-39ef-1dc4-917b533fab3f/CleanShot_2025-01-31_at_07.44.33@2x.jpg/1320x2868.png)







## ACTPlus Available In
- [Argentina](https://apptail.io/app/actplus-cxvv/argentina)
- [China](https://apptail.io/app/actplus-cxvv/china)
- [Germany](https://apptail.io/app/actplus-cxvv/germany)
- [Estonia](https://apptail.io/app/actplus-cxvv/estonia)
- [Finland](https://apptail.io/app/actplus-cxvv/finland)
- [France](https://apptail.io/app/actplus-cxvv/france)
- [Greece](https://apptail.io/app/actplus-cxvv/greece)
- [Croatia](https://apptail.io/app/actplus-cxvv/croatia)
- [Hungary](https://apptail.io/app/actplus-cxvv/hungary)
- [Indonesia](https://apptail.io/app/actplus-cxvv/indonesia)
- [Jordan](https://apptail.io/app/actplus-cxvv/jordan)
- [Japan](https://apptail.io/app/actplus-cxvv/japan)
- [Latvia](https://apptail.io/app/actplus-cxvv/latvia)
- [North Macedonia](https://apptail.io/app/actplus-cxvv/north-macedonia)
- [Malta](https://apptail.io/app/actplus-cxvv/malta)
- [Norway](https://apptail.io/app/actplus-cxvv/norway)
- [Portugal](https://apptail.io/app/actplus-cxvv/portugal)
- [Russia](https://apptail.io/app/actplus-cxvv/russia)
- [Slovenia](https://apptail.io/app/actplus-cxvv/slovenia)
- [Senegal](https://apptail.io/app/actplus-cxvv/senegal)
- [Türkiye](https://apptail.io/app/actplus-cxvv/turkey)
- [Ukraine](https://apptail.io/app/actplus-cxvv/ukraine)

---

## About AppTail

[AppTail](https://apptail.io) is a mobile app intelligence platform providing app analytics, ASO (App Store Optimization) tools, keyword tracking, competitor analysis, revenue estimates, and review monitoring for iOS App Store apps. Track your app's performance, discover ranking keywords, monitor competitors, and analyze market trends.

- [Search Apps](https://apptail.io)
- [Top Charts](https://apptail.io/top-iphone-apps)
- [Sign Up for Full Access](https://app.apptail.io/signup?utm_campaign=ai-crawl&amp;utm_content=footer)

*Data provided by [AppTail](https://apptail.io) - Mobile App Intelligence Platform*
